C12N 2501/06
Anti-neoplasic drugs, anti-retroviral drugs
Official title: Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
C12N2501/06 (Anti-neoplasic drugs, anti-retroviral drugs) appears on 126 US grants and 248 published applications in this corpus.
Search patents in C12N- Granted patents
- 126
- Published applications
- 248
- Assignees
- 152
- Inventors
- 477
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 2 |
| 2002 | 1 | 7 |
| 2003 | 2 | 10 |
| 2004 | 0 | 4 |
| 2005 | 2 | 14 |
| 2006 | 2 | 4 |
| 2007 | 4 | 4 |
| 2008 | 4 | 7 |
| 2009 | 3 | 6 |
| 2010 | 6 | 8 |
| 2011 | 4 | 16 |
| 2012 | 4 | 11 |
| 2013 | 7 | 11 |
| 2014 | 5 | 8 |
| 2015 | 5 | 16 |
| 2016 | 9 | 16 |
| 2017 | 8 | 10 |
| 2018 | 13 | 6 |
| 2019 | 8 | 19 |
| 2020 | 5 | 7 |
| 2021 | 3 | 19 |
| 2022 | 8 | 9 |
| 2023 | 3 | 11 |
| 2024 | 2 | 8 |
| 2025 | 4 | 7 |
| 2026 | 5 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion7 Jul 2026US 12,673,982 B2Iovance Biotherapeutics, Inc.
- Methods for reprogramming cells and uses thereof12 May 2026US 12,624,342 B2Genesis Technologies Limited
- Methods to induce terminal differentiation in stem cells by interfering with DNA replication, methods of inducing pancreatic differentiation, and differentiated cells obtained thereof21 Apr 2026US 12,605,407 B2The Trustees of Columbia University in the City of New York
- Xeno-free and transgene-free reprograming of mesenchymal stem cells toward neural progenitor cells17 Mar 2026US 12,577,532 B2Institute for Scientific Research and Technology Services (Indicasat)
- Superparamagnetism-modified and neutrophil exosome biomimetic vesicle-based biological preparation for drug delivery, and preparation method thereof10 Feb 2026US 12,544,452 B2Jiangsu University
- Method for producing high-titer viral vector8 Oct 2026US 2026/0308534 A1Kaneka Corporation
- Pluripotent stem cell that can be isolated from body tissue1 Oct 2026US 2026/0297512 A1MuseCell Innovations Pte. Ltd.
- Xeno-free and transgene-free reprograming of mesenchymal stem cells toward neural progenitor cells1 Oct 2026US 2026/0297516 A1
- Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion17 Sep 2026US 2026/0274920 A1Iovance Biotherapeutics, Inc.
- Homology-independent targeted dna insertion in human t cells16 Jul 2026US 2026/0201420 A1The Board of Trustees of the Leland Stanford Junior University
Most cited
By later US patents
- Lineage-directed induction of human mesenchymal stem cell differentiation264US 5,736,396 ACase Western Reserve University · 1998
- Lineage-directed induction of human mesenchymal stem cell differentiation212US 5,942,225 ACase Western Reserve University · 1999
- Method of increasing the relative number of CD34.sup.+ cells in a cell population44US 6,090,625 A2000
- Remnant tumor infiltrating lymphocytes and methods of preparing and using the same27US 11,220,670 B2Iovance Biotherapeutics, Inc. · 2022
- Remnant tumor infiltrating lymphocytes and methods of preparing and using the same27US 11,293,009 B2Iovance Biotherapeutics, Inc. · 2022